School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Precision BioSciences, Inc. DTIL

Healthcare · Biotechnology

$6.72last close 2026-10-09 · market cap $185.48M · delayed data

Trailing returns

1M-7.31%
3M-26.64%
6M+1.66%
1Y+14.29%
5Y-97.80%

Basis: Adjusted daily closes.

What it does

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.

Open DTIL in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies